To assess the effectiveness of Systane COMPLETE in improving meibomian gland score and in reducing symptoms of ocular dryness

TL;DR

This study shows that Systane COMPLETE improves dry eye symptoms and objective measures in patients with mild to moderate dry eye disease.

Contribution

The study demonstrates the effectiveness of a lipid-based nanoemulsion in improving meibomian gland function and dry eye symptoms.

Findings

Significant improvements in tear breakup time, Schirmer’s test, and lipid layer thickness were observed.

OSDI scores and corneal staining scores improved significantly after treatment.

Meibomian gland score change was not statistically significant.

Abstract

To assess the effectiveness of Systane COMPLETE in reducing symptoms of ocular dryness and improving Meibomian Gland (MG) Score in subjects with mild to moderate dry eye disease (DED).

A prospective, interventional, single-center, single-arm study was conducted including cases of mild to moderate DED. Participants were prescribed a topical lipid-based combination of propylene glycol (PG) and hydroxypropyl guar (HPG) (Systane® COMPLETE), administered four times daily for 30 days. Dry eye assessment parameters, Meibo score, and Ocular Surface Disease Index (OSDI) questionnaire responses were obtained before and after treatment.

A total of 105 cases with mild to moderate DED were included in the study. Statistically significant improvements were observed in tear breakup time (TBUT) (p<0.0001), Schirmer’s test (p<0.0001), lipid layer thickness (LLT) (p<0.0001), tear meniscus height (TMH) (p=0.0002), non-invasive breakup time (NIBUT) (p<0.0001), OSDI (p<0.0001), upper lid meibomian gland score (p=0.02), corneal staining score (p<0.0001). The change in Meibo score was not statistically significant (p=0.19).

A lipid-based nanoemulsion of PG–HPG helps in improving the objective parameters and symptoms of DED. Additionally, it may support improved meibomian gland function.

Figures